Prediction of hematologic toxicity after radioimmunotherapy with 131I-labeled anticarcinoembryonic antigen monoclonal antibodies

Journal of Nuclear Medicine

Volumn 40, Issue 10, 1999, Pages 1609-1616

  Juweid, Malik E ^a,b   Zhang, Cun Hui ^a   Blumenthal, Rosalyn D ^a   Hajjar, George ^a   Sharkey, Robert M ^a   Goldenberg, David M ^a  

^a Ctr for Molec Med and Immunology   (United States)

^b GARDEN STATE CANCER CENTER   (United States)

Author keywords

Cancer; Carcinoembryonic antigen; Hematologic toxicity; Monoclonal antibodies; Radioimmunotherapy; Red marrow dosimetry

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY I 131;

ARTICLE; BONE MARROW; BONE MARROW METASTASIS; BONE MARROW TOXICITY; BONE METASTASIS; BREAST CANCER; COLORECTAL CANCER; FEMALE; HUMAN; LEUKOCYTE COUNT; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; THROMBOCYTE COUNT; THYROID CANCER;

AGE FACTORS; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; BLOOD CELL COUNT; BONE MARROW; CARCINOEMBRYONIC ANTIGEN; FEMALE; HEMATOLOGIC DISEASES; HUMANS; IODINE RADIOISOTOPES; LEUKOPENIA; MALE; NEOPLASM METASTASIS; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SEX FACTORS; THROMBOCYTOPENIA;

EID: 0032886681     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Larson SM, Leibel SA, Cheung NKV. Radioisotope conjugates. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. Philadelphia, PA: JB Lippincott; 1991:496-511.
2. Goldenberg DM. Monoclonal antibodies in cancer detection and therapy. Am J Med. 1993;94:297-312.
3. DeNardo GL, DeNardo SJ, Macey DJ, Shen S, Kroger LA. Overview of radiation myelotoxicity secondary to radioimmunotherapy using I-131-Lym-1 as a model. Cancer. 1994;73:1038-1048.
4. 2. J Nucl Med. 1996;37:1504-1510.
5. 131I-labeled anti-CEA antibodies. J Nucl Med. 1996;37:905-911.
6. 131I-labeled anti-CEA murine monoclonal antibody IgG. J Nucl Med. 1997;38:858-870.
7. 131I-CC49 in colorectal cancer. Cancer. 1994;73:1057-1066.
8. Meredith RF, Bueschen AJ, Khazaeli MB, et al. Treatment of metastatic prostate cancer with radiolabeled antibody CC49. J Nucl Med. 1994;35:1017-1022.
9. Divgi CR, Scott AM, Dantis L, et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med. 1995;36:586-592.
10. Welt S, Divgi CR, Kemeny N, et al. Phase I/II study of iodine-131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol. 1994;12:1561-1571.
11. Breitz HB, Fisher DR, Wessels B. Correlation of bone marrow absorbed dose estimates with marrow toxicity [abstract]. Tumor Targeting. 1996;2:171-172.
12. Behr TM, Sharkey RM, Juweid M, et al. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors. Cancer Res. 1996;56: 1805-1816.
13. 2. Cancer. 1996;78:157-168.
14. Yu B, Carrasquillo DM, Chung Y, et al. Phase I trial of iodine-131-labeled COL in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinectics. J Clin Oncol. 1996;14:1798-1809.
15. 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial. Cancer Res. 1995;55(suppl):5929s-5934s.
16. Primus FJ, Newell KD, Blue A, Goldenberg DM. Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies. Cancer Res. 1983;43:686-692.
17. Sharkey RM, Goldenberg DM, Goldenberg H, et al. Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinectic and targeting properties in humans. Cancer Res. 1990;50:2823-2831.
18. Hansen HJ, Goldenberg DM, Newman E, Grebenau R, Sharkey RM. Characterization of second generation monoclonal antibodies against carcinoembryonic antigen. Cancer. 1993;71:3478-3485.
19. Sharkey RM, Goldenberg DM, Murthy S, et al. Clinical evaluation of tumor targeting with a high affinity anticarcinoembryonic-antigen-specific, murine monoclonal antibody. MN-14. Cancer. 1993;71:2081-2096.
20. Weadock KS, Sharkey RM, Varga DC, Goldenberg DM. Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med. 1990;31:508-511.
21. Bigler R, Zanzonico PB, Leonard R, et al. Bone marrow dosimetry for monoclonal antibody therapy. In: Schlate-Stelson AT, Watson EE, eds. Proceedings of the Fourth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge, TN: Oak Ridge Associated Universities; 1986:535-544.
22. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm. 1990;3:213-233.
23. Fisher DR. Radiation dosimetry for radioimmunotherapy. Cancer. 1994;73:905-911.
24. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694.
25. Synder W, Ford M, Warner G, Watson E. "S," Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. MIRD pamphlet no. 11. New York, NY: Society of Nuclear Medicine; 1975.
26. Cloutier RV, Watson EE, Rohrer RH, et al. Calculating the radiation dose to an organ. J Nucl Med. 1973;14:53-55.
27. Weisberg S. Applied Linear Regression. New York, NY: Wiley; 1985.
28. Johnson RA, Wichern DW. Applied Multivariate Statistical Analysis. Englewood Cliffs, NJ: Prentice-Hall; 1988.
29. Chabner BA. Anticancer drugs. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practices of Oncology. Philadelphia, PA: JB Lippincott; 1993:325-417.
30. Blumenthal RD, Alisauskas R, Juweid M, Sharkey RM, Goldenberg DM. Defining the optimal spacing between repeat radioantibody doses in experimental models: is there an accurate toxicity endpoint [abstract]? Tumor Targeting. 1996; 2:151-152.
31. Loeffler M, Wichman HE. A comprehensive mathematical model of stem cell proliferation which reproduces most of the published experimental results. Cell Tissue Kinet. 1980;13:543-561.
32. Reske SN, Karstens JH, Gloeckner MW, et al. Radioimmunoimaging of bone marrow: results in patients with breast cancer and skeletal metastases and patients with malignant melanoma. Lancet. 1989;2:299-301.
33. Duncker CM, Carrio I, Berna L, et al. Radioimmune imaging of bone marrow in patients with suspected bone metastases from primary breast cancer. J Nucl Med. 1990;31:1450-1455.
34. 99mTc-MDP bone scan. Korean J Nucl Med. 1994;28:89-97.